TY - JOUR
T1 - KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas
AU - Dias-Santagata, D.
AU - Selim, M. A.
AU - Su, Y.
AU - Peng, Y.
AU - Vollmer, R.
AU - Chłopik, A.
AU - Tell-Marti, G.
AU - Paral, K. M.
AU - Shalin, S. C.
AU - Shea, C. R.
AU - Puig, S.
AU - Fernandez-Figueras, M. T.
AU - Biernat, W.
AU - Ryś, J.
AU - Marszalek, A.
AU - Hoang, M. P.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - © 2017 British Association of Dermatologists Background: Few studies have addressed prognostic markers and none has correlated molecular status and prognosis in vulvar melanomas. Objectives: To evaluate the clinicopathological features of 95 cases of vulvar melanoma. Methods: p53, CD117, Ki-67, neurofibromin, brafv600e and nrasq61r immunostains, and molecular analyses by either targeted next-generation or direct sequencing, were performed on available archival materials. Results: Molecular testing detected mutations in KIT (44%), BRAF (25%), NF1 (22%), TP53 (17%), NRAS (9%) and TERT promoter (9%). Co-mutation of KIT and NF1 and of KIT and NRAS were identified in two and one cases, respectively. KIT mutations were significantly associated with better progression-free survival in univariate analyses. In multivariate analyses CD117 expression was significantly associated with better progression-free survival. Tumour thickness was significantly associated with worse progression-free and overall survival, and perineural invasion significantly correlated with reduced melanoma-specific survival and reduced overall survival. Cases were from multiple centres and only a subset of samples was available for molecular testing. Conclusions: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.
AB - © 2017 British Association of Dermatologists Background: Few studies have addressed prognostic markers and none has correlated molecular status and prognosis in vulvar melanomas. Objectives: To evaluate the clinicopathological features of 95 cases of vulvar melanoma. Methods: p53, CD117, Ki-67, neurofibromin, brafv600e and nrasq61r immunostains, and molecular analyses by either targeted next-generation or direct sequencing, were performed on available archival materials. Results: Molecular testing detected mutations in KIT (44%), BRAF (25%), NF1 (22%), TP53 (17%), NRAS (9%) and TERT promoter (9%). Co-mutation of KIT and NF1 and of KIT and NRAS were identified in two and one cases, respectively. KIT mutations were significantly associated with better progression-free survival in univariate analyses. In multivariate analyses CD117 expression was significantly associated with better progression-free survival. Tumour thickness was significantly associated with worse progression-free and overall survival, and perineural invasion significantly correlated with reduced melanoma-specific survival and reduced overall survival. Cases were from multiple centres and only a subset of samples was available for molecular testing. Conclusions: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.
U2 - 10.1111/bjd.15836
DO - 10.1111/bjd.15836
M3 - Article
VL - 177
SP - 1376
EP - 1384
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 5
ER -